Effectiveness of Trans-Arterial Chemo Embolization for Hepatocellular Carcinoma on Follow-Up CT Triphasic Liver

NCT ID: NCT07048665

Last Updated: 2025-07-02

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Total Enrollment: 60 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-03-17
• Study Completion Date: 2026-02-28

Brief Summary

"HCC is a major challenge due to greater recurrence rates and variable treatment responses. TACE is widely used, but its success relies on accurate follow-up imaging. CT Triphasic Liver Imaging plays a vital role in assessing treatment response, guiding clinical decisions, and improving patient outcomes. The purpose of this study is to investigate the relationship between response of treatment, gender, age, and the cause of HCC. The purpose of the study is to evaluate how well TACE (trans-arterial chemoembolization) works for patients with HCC.

Detailed Description

This will be a retrospective observational study aimed at evaluating the effectiveness of Trans-Arterial Chemo-Embolization in the management of Hepatocellular Carcinoma (HCC) using follow-up CT Triphasic Liver imaging. Patient records and imaging data from past cases will be reviewed to assess post- treatment tumor response and progression.

Conditions

Hepatocellular Carcinoma

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: RETROSPECTIVE

Study Groups

CT Images

CT Imagesa in HCCT

Intervention Type: DIAGNOSTIC_TEST

Cross-sectional imaging with computed tomography (CT) scanning and magnetic resonance imaging (MRI) is most commonly used to detect hepatocellular carcinoma (HCC). CT scanning is frequently the first examination; however, MRI has superior contrast resolution and may better detect lesions less than 1 cm in diameter

Interventions

CT Imagesa in HCCT

Cross-sectional imaging with computed tomography (CT) scanning and magnetic resonance imaging (MRI) is most commonly used to detect hepatocellular carcinoma (HCC). CT scanning is frequently the first examination; however, MRI has superior contrast resolution and may better detect lesions less than 1 cm in diameter

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

• Both Male and Female.
• Patients diagnosed with HCC who underwent TACE.
• Patients with no portal vein tumor thrombus (PVTT) or no extra Extrahepatic Metastases at the time of initial TACE treatment.
• Patients who underwent TACE within last your years from the study start date.

Exclusion Criteria

• Patients with incomplete or missing medical records and imaging studies.
• Patients with a history of severe comorbidities that might interfere with treatment response evaluation
• Patients who were contraindicated for CT scans at the time of follow-up.
• Patients that are contradicted with CT scan.
• Patient who underwent TACE more than four years before the study period.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Superior University

OTHER

Sponsor Role: lead

Responsible Party

Muhammad Naveed Babur

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

AYK Hospital

Lahore, , Pakistan

Countries

Pakistan

Other Identifiers

MSAHSW/Batch-Fall23/906

Identifier Type: -

Identifier Source: org_study_id